18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Lanell M. Peterson; Brenda F. Kurland; Fengting Yan; Alena Novakova- Jiresova; Vijayakrishna K. Gadi; Jennifer M. Specht; Julie R. Gralow; Erin K. Schubert; Jeanne M. Link; Kenneth A. Krohn; Janet F. Eary; David A. Mankoff; Hannah M. Linden

doi:10.2967/jnumed.120.244459

Research ArticleOncology

¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Lanell M. Peterson, Brenda F. Kurland, Fengting Yan, Alena Novakova- Jiresova, Vijayakrishna K. Gadi, Jennifer M. Specht, Julie R. Gralow, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Janet F. Eary, David A. Mankoff and Hannah M. Linden

Journal of Nuclear Medicine February 2021, 62 (2) 184-190; DOI: https://doi.org/10.2967/jnumed.120.244459

Lanell M. Peterson

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Brenda F. Kurland

2Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fengting Yan

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alena Novakova- Jiresova

3Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vijayakrishna K. Gadi

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

4Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jennifer M. Specht

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Julie R. Gralow

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erin K. Schubert

5Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeanne M. Link

6Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kenneth A. Krohn

6Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Janet F. Eary

7Cancer Imaging Program, National Cancer Institute, Bethesda, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David A. Mankoff

5Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hannah M. Linden

1Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 2

February 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Journal of Nuclear Medicine Feb 2021, 62 (2) 184-190; DOI: 10.2967/jnumed.120.244459

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Journal of Nuclear Medicine Feb 2021, 62 (2) 184-190; DOI: 10.2967/jnumed.120.244459

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Oncology

Emerging practice in the FDG-PET studies of testicular cancer
Risk Stratification in Diffuse Large B Cell Lymphoma: A Review of Novel FDG PET/CT Imaging and Liquid Biopsy Biomarkers and Suggestions for Future Directions to Improve Prognostic Accuracy
PET/CT Findings: Langerhans Cell Sarcoma Arising from Langerhans Cell Histiocytosis

Show more Oncology

Clinical

Emerging practice in the FDG-PET studies of testicular cancer
Risk Stratification in Diffuse Large B Cell Lymphoma: A Review of Novel FDG PET/CT Imaging and Liquid Biopsy Biomarkers and Suggestions for Future Directions to Improve Prognostic Accuracy
PET/CT Findings: Langerhans Cell Sarcoma Arising from Langerhans Cell Histiocytosis

Show more Clinical

Keywords

FES
vorinostat
ER+ breast cancer
metastatic breast cancer
estrogen receptors

Main menu

User menu

Search

¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Clinical

Similar Articles

Keywords